brontictuzumab + trifluridine + tipiracil

This drug is a combination of three agents: **brontictuzumab**, **trifluridine**, and **tipiracil**. - **Brontictuzumab** is a monoclonal antibody targeting Notch1, a protein involved in cell differentiation and proliferation, with proposed antitumor activity in certain cancers (primarily solid tumors). - **Trifluridine** is a nucleoside analog that gets incorporated into DNA during synthesis, disrupting DNA replication and causing cytotoxicity by inhibiting thymidylate synthase. - **Tipiracil** is a thymidine phosphorylase inhibitor that prevents the rapid degradation of trifluridine, increasing its bioavailability. The combination aims to leverage both targeted therapy (Notch1 inhibition by brontictuzumab) and cytotoxic chemotherapy (trifluridine/tipiracil), potentially for advanced solid tumors such as metastatic colorectal cancer, though no clinical combination of these three agents is documented as of September 2025. Trifluridine/tipiracil is approved for metastatic colorectal and gastric cancer[1][3].